Congestive heart failure is a chronic heart condition that usually occurs in older people However people with a history of ...

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, will highlight the latest sudden cardiac death research, case experiences for heart failure readmission ...

Researchers at the University of Bristol have identified a specific biological mechanism by which GLP-1 drugs, the same class ...

Sanjay Bhojraj, a cardiologist who has spent 20 years treating heart attacks, shares evening habits that influence heart ...

BioCardia ®, Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its ...

Also, for the first time, doctors are advised to test for two biomarkers in the blood that have been linked to increased risks of heart disease.

Background Endovascular therapy (EVT) is standard treatment for large vessel occlusion in patients with a National Institutes ...

Geography once drove disparity, but access now hinges on how effectively centers can employ modern donor-utilization tools.

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...

A new study suggests that widely used GLP-1 weight-loss drugs may do more than improve metabolic health: they could also protect the heart after a heart attack. Doctors can often reopen the blocked ...

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...